At long last, we finally have a disease-modifying drug for Alzheimer’s. The FDA recently approved a new drug that promises to slow the progression of the disease. Only five Alzheimer’s treatments have been approved by the FDA up until a decade ago, and this is only the second to address the progression of the disease.
FDA-approved ADLARITY is the once-weekly donepezil patch. See how it compares to donepezil / Aricept / Ebixa tablets for Alzheimer’s.
Swedish researchers find that cholinesterase inhibitors provide cognitive benefits and reduce mortality for up to five years after an Alzheimer’s diagnosis. One medication significantly reduced the risk of developing severe dementia.
Now, a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA),. The field of new drugs is beginning to show progress in the fight to slow the disease.
First drug to modestly slow Alzheimer’s cognitive decline, based on 1,800 patients.
The FDA Advisory Committee’s endorsement of Leqembi paves way for traditional approval, ushers in a new era for Alzheimer’s
Researchers find that people with dementia who received the drug suvorexant showed a drop in tau and amyloid beta. The drug is already available for sleep problems in Alzheimer’s. Learn more.
NAMENDA® / EBIXA® (generic MEMANTINE) is FDA-approved for Alzheimer’s. Learn about new research on how it may help in preventing or slowing dementia.
Research shows that lecanemab is the first drug ever to slow cognitive decline in Alzheimer’s. Learn more.
People with Alzheimer’s are often prescribed drugs for other conditions — including diabetes or high blood pressure — at the same doses as those without dementia. That practice might need to be reexamined.
Dr. Rudy Tanzi is Professor of Neurology at Harvard Medical and Director of McCance Center for Brain Health. Based on 3 decades of his research, learn how CogniSHIELD uniquely protects against amyloid, inflammation and Alzheimer’s.
See Prime Minister Harold Wilson tell Queen Elizabeth he has Alzheimer’s. It’s a deeply human moment between sovereign and statesman, marked by quiet dignity, personal sorrow, and the recognition that even the sharpest minds can’t escape time’s reach.
Trontinemab, an experimental drug developed by Roche, has sparked excitement in large trials for slowing Alzheimer’s faster and safer than anything before.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
No spam, only news and updates.
